FDA Clarifies Scope Of Its Emerging Technology Program

FDA’s final guidance on a program for encouraging the use of continuous manufacturing and other new pharmaceutical technologies clarifies the types of emerging technologies that are eligible for review under the agency's Emerging Technology Program.

The guidance also permits FDA's Office of Regulatory Affairs and the Office of Compliance in the agency's Center for Drug Evaluation and Research to review applications and conduct on-site reviews...